Full text is available at the source.
Abstract
Heart failure is a major cardiovascular complication of type 2 diabetes mellitus.
- Sodium-glucose cotransporter-2 inhibitors may improve cardiovascular outcomes in patients with heart failure.
- Glucagon-like peptide-1 receptor agonists are also associated with better cardiovascular results.
- The comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in heart failure is not clearly established.
- The potential benefits of using both SGLT2 inhibitors and GLP-1 receptor agonists together for heart failure management remain uncertain.
Simplified